

Clindabactin 440 mg Chewable Tablets for Dogs

Authorised

- Clindamycin hydrochloride

Product identification

Medicine name:

Clindabactin 440 mg Chewable Tablets for Dogs

Active substance:

Clindamycin hydrochloride

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Clindamycin hydrochloride
440.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01FF01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Norway

Available in:

Norway

Package description:

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets.

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box of 8 blisters of 10 tablets.

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box of 6 blisters of 10 tablets.

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box of 4 blisters of 10 tablets.

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box of 3 blisters of 10 tablets.

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box of 25 blisters of 10 tablets.

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box of 1 blister of 10 tablets.

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box of 9 blisters of 10 tablets.

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box of 7 blisters of 10 tablets.

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box of 5 blisters of 10 tablets.

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box of 2 blisters of 10 tablets.

Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box of 10 blisters of 10 tablets.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Dechra Regulatory B.V.

Marketing authorisation date:

24/06/2019

Manufacturing sites for batch release:

Lelypharma B.V.

Genera d.d.

Responsible authority:

Norwegian Medical Products Agency

Authorisation number:

18-12138

Date of authorisation status change:

1/05/2021

Reference member state:

Netherlands

Procedure number:

NL/V/0317/003

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland
France Germany Hungary Iceland Ireland Italy Latvia Lithuania

Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain
Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Clindabactin 55 220 en 440 mg - Puar.pdf